Information Provided By: 
Fly News Breaks for February 24, 2020
GMAB
Feb 24, 2020 | 07:18 EDT
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Genmab to $29 from $25 and reiterates a Buy rating on the shares. The analyst believes 2020 is likely to be a "watershed year" for Genmab's pipeline. He sees clear efficacy signals for the CD20xCD3 bispecifics, with a potential convenience advantage for epcoritamab.
News For GMAB From the Last 2 Days
There are no results for your query GMAB
